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ABSTRACT 
Recently, a significant number of studies regarding the environmental occurrence and fate 
of pharmaceuticals and personal care products (PPCPs) used in developed countries has 
been published. In the developing world, different therapeutic groups are frequently used 
without the knowledge of their behavior in the aquatic and terrestrial ecosystems. Great 
number of pharmaceuticals detected from the natural ecosystems around the world and the 
reported impact on non-target organisms suggest that PPCPs are potent and persistent 
environmental pollutants. 
The herein presented study, conducted with the support of pharmaceutical company in 
Nairobi; Kenya, analyzed the biodegradation potential of seventeen selected 
pharmaceuticals typical for the developing world. The test method was based on the 
Organization for Economic Co-operation and Development (OECD) 301 guidelines and 
OxiTop
®
-C 110 system was employed in the measurement. The principle of the 
measurement was manometric respirometry in a closed bottle system measuring the 
microbial activity by carbon dioxide evolution. Dextrose monohydrate and carbamazepine 
were selected to test the functionality of the system and to connect to the literature data. 
Only two drugs from seventeen were readily biodegradable. All tested antiviral drugs, 
antimalarials, antiparasitics, antifungals, antituberculotics, antibacterials, and 
antiulceratives were found non-degradable, potentially persistent in the environment or 
affecting the efficiency of wastewater treatment plant (WWTP) processes.  
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1 Introduction 
The occurrence and fate of anthropogenic chemical species in our environment has been 
given great attention for several decades already. The main areas of research were however 
limited to solvents, detergents and agricultural chemicals. Only during the last two decades, 
the attention has shifted towards therapeutics (Halling-Sørensen, 1998, Kümmerer, 2004). 
Therapeutic or pharmaceutical chemicals are biologically active ingredients that are 
initially planned to increase or moderate the quality of human health. Recent studies 
however suggest that pharmaceuticals and their residues are refractory compounds 
persisting in the environment and affecting non-target species in aquatic and terrestrial 
ecosystems (Boxall, 2006, Heberer, 2002, Vieno, 2007, Quinn, 2008, Wollenberger, 2000). 
Pharmaceuticals and Personal Care Products (PPCPs) have been recognized as a potential 
environmental problem (Kümmerer, 2004). The research on the occurrence and on the fate 
of PPCPs in the environment has been active particularly in Europe and USA (Carballa 
Arcos, 2005, Lishman, 2006).  
Recent studies provide knowledge on the PPCPs frequently used in developed countries 
(Kasprzyk-Horden, 2009, Gros, 2009, Ternes, 1998). However the use, occurrence, fate, 
biotic and abiotic degradation of therapeutics commonly used in developing countries has 
not been widely studied. In other words, the ecotoxicological knowledge on PPCPs such as 
antimalarials, antiretrovirals, antituberculotics and antiparasitics is incomplete.   
Furthermore, the pressure to develop innovative methods to improve the removal 
efficiencies of the anthropogenic pollutants from the hydrologic cycle is increasing 
(Sangave, 2007, Rosal, 2010, Badawy, 2009). Efficient removal of refractory compounds 
would make the recycling of industrial wastewater possible for irrigation (Badawy, 2009). 
Closing water loop is one of the options to sustain and minimize the water resource 
exploitation. Limited quantity of unpolluted water, especially for agricultural purposes in 
the future, is one of the major challenges of the world (Ternes, 2007). Mainly in sub-
Saharan Africa, over-exploration of limited water sources is resulting in decreasing river 
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flows, falling groundwater levels, increasing water pollution and wetland deterioration 
(Descheemaeker, 2010).  
This thesis has been a part of co-operation of Tampere University of Technology (TUT), 
Tampere, Finland, and Tampere University of Applied Science (TAMK), Tampere, 
Finland. The project has been supported by pharmaceutical industry Universal Corporation 
Limited (UCL), Nairobi, Kenya.  
1.1 Objectives of the study 
The target of the herein presented work is to determine biodegradability of selected PPCPs. 
Biodegradation screening is included as a part of the work. Results of the screening are 
consecutively used to identify non-biodegradable compounds. These chemicals may 
include e.g. refractory compounds persistent in the environment, therapeutics affecting 
bacterial species in their natural ecosystems, or toxic and inhibitory chemicals reducing 
efficiency of biological processes in wastewater treatment plant.   
1.2 Scope 
From a large portfolio of pharmaceutical therapeutic groups used frequently in developing 
world, 19 chemicals were selected for the biodegradability analysis. The main selection 
parameters were the therapeutic use, water solubility and the lacking knowledge of the 
occurrence, fate and behavior in the environment. 
1.3 Outline 
The structure of the thesis is as follows. Chapter 2 provides a review of reported 
occurrence, fate and effects of pharmaceuticals in the environment. Chapter 3 introduces 
the methods available for biodegradability measurements. Chapter 4 concentrates on the 
background information of the pharmaceuticals selected for the study. Chapter 5 describes 
the experimental setup of the biodegradability screening. Chapter 6 presents the results and 
observations on the analysis, and Chapter 7 concludes and provides proposals for future 
work.  
2 Pharmaceuticals in the environment 
During last two decades the interest in the occurrence and fate of pharmaceuticals and 
personal care products (PPCPs) in the environment has risen dramatically. The main reason 
of the concern has been rapidly increasing consumption of medical preparations as well as 
fast development of semi-synthetic and synthetic derivates. Today there are over 100,000 
chemical individuals on the market prescribed all over the world (Merck, 2006, Sweetman, 
2007, Hardman, 2001).  
Another reason for the growing attention to medical substances is the intention of 
performing a biological effect. Chemical derivates of naturally occurring compounds are 
designed to be potent, species selective or with a broad spectrum of target organisms. The 
concern of the development is the change in physico-chemical properties for better 
membrane penetration, increased toxicity to either target or non-target organism, and 
possible persistence causing accumulation in the terrestrial and aquatic ecosystems. The 
constant exposure might cause development of resistant strains of bacteria, affect plant 
growth or animal and human health.    
2.1 Pathways of exposure 
Figure 1 presents the pathways possibly undertaken by human and veterinary 
pharmaceuticals in the environment starting from the sources, through the exposure routes 
to the receiving ecosystems. Parameters affecting the speed of the passage and severity of 
the impact in the receiving ecosystem can be found in the same figure. Such important 
parameters are physico-chemical properties, quantities prescribed, produced or excreted, 
and the spectrum of animal, plant and micro-organic species affected. The final severity of 
the PPCPs impact is given by the persistence in the environment influenced by the 
pharmaceutical degradation rate.  
For safe sustainable development, fresh water needs to be free of those persistent non-
degradable PPCPs. So that closing water loop would not continue the pharmaceutical 
circulation in the environment causing constant re-exposure to xenobiotic chemicals.     
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Figure 1 Exposure pathways of PPCPs in the environment 
2.2 Reported fate of PPCPs in the environment 
Most pharmaceuticals undergo metabolic changes after being digested and absorbed in the 
target organism. Many medical compounds are metabolized to Phase I or Phase II 
metabolites (Halling-Sørensen, 1998, Kümmerer, 2004). Phase I reactions consist of 
reduction, oxidation, hydrolysis, alkylation or dealkylation giving often more reactive or 
more toxic compounds compared to the parent pharmaceutical. Phase II metabolites (e.g. 
hydroxylated compounds) are Phase I metabolites modified by glucuronation or sulfatation. 
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Phase II compounds are often inactive but more water soluble conjugates for enhanced 
excretion. 
The active compound after it is excreted by the recipient via urine or feces can appear in the 
sewage system as a parent active compound or in the form of more water soluble 
metabolites (Heberer, 2002). The disposal of PPCPs and their residuals via municipal 
sewage systems seems of minor interest; however the metabolites can be transformed by 
sludge bacteria back into the potent parent compound. Furthermore, large number of the 
therapeutics is excreted unchanged conjugated to polar molecules, glucuronides. The 
conjugates can be during the wastewater treatment cleaved into the original parent 
compound and enter the natural aquatic and terrestrial ecosystems. Pharmaceuticals that are 
disposed incorrectly to the sewage system or dumpsite, or appear in the wastewater through 
the industrial production are present in active forms, dissolved or as suspended solids.  
Fate of individual pharmaceuticals in the environment can differ dramatically. The main 
fate processes in the environment is sorption and (bio)degradation, photodegradation and 
hydrolysis can be also significant (Kümmerer, 2004). Depending on the toxicity of the 
compound towards microorganisms, stability in the presence of air or light, PPCPs can 
persist for years in our surroundings. For example pentobarbital has been detected in 21 
years old anaerobic ground water plume (Eckel, 1993); oxytetracycline, oxolinic acid, 
flumequine and sarafloxacine have been detected in sediments of fish farms several months 
after application to the water (Halling-Sørensen, 1998).    
Most current studies on the fate of PPCPs are performed on the WWTP influent and 
effluent concentrations. The detection from municipal sewage and comparison of WWTP 
influent and effluent concentrations gives the quantity of therapeutics entering natural 
ecosystems. Furthermore the efficiency of the WWTP and the possible removal of the 
pharmaceuticals can be drawn to evaluate pharmaceutical persistence. For example 
chloramphenicol removal has been measured (Kasprzyk-Horden, 2009) from 95 to 100%. 
50% of erythromycin-H2O and 70% of sulphamethoxazole have been removed during 
wastewater treatment in Wales, UK. Carbamazepine, tramadol, and β-blockers (atenolol) 
however have not been removed during the same treatment process. Ibuprofene, 
paracetamol, salbutamol and mefenamic acid (Jones, 2007) have been studied on the 
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removal in southern England. Even though all chemicals were removed by more than 90% 
compared to the influent concentration, residues of all compounds were found in the 
effluent. 
Large number of research studies on the fate of pharmaceuticals in the developed world 
uses the available detail knowledge of consumption patterns and amounts of PPCPs 
consumed (Winker, 2008, Lindqvist, 2005). The comparison of quantity consumed (and 
excreted via urine or feces to sewage system) to the quantity detected in the WWTP 
influent/effluent gives needed knowledge on the removal efficiency during the WWTP 
processes. A study conducted in Finland furthermore compares removal efficiencies of 
different WWTP that employ different sets of wastewater treatment processes (Vieno, 
2007). Correct selection of physical, biological and chemical treatments could increase the 
removal efficiency rapidly (Kreuzinger, 2004). In the Finnish study, the removal of atenolol 
ranged from 37% to 77% in different WWTP.    
The amount of pharmaceutical residues, that passes the WWTP barrier and enter the natural 
environment, and the possibility to develop or improve the WWTP processes to increase 
the removal are another great positives of the detailed knowledge on the prescription. The 
same methods of monitoring can be hardly applied to the research in developing countries. 
Main reason is unknown or inaccurate quantities of PPCPs consumed and insufficient 
sanitation or centralized sewage system.   
2.3 Reported occurrence of PPCPs in the environment  
The occurrence of the therapeutics in the environment has been already intensively 
investigated for more than 15 years. However research studies available provide knowledge 
mainly on pharmaceuticals and personal care products (PPCPs) used and detected in 
developed countries (Austria, Canada, USA, Germany, Denmark, Finland, Sweden, 
Norway, Spain and Netherlands).  
More than 80 PPCPs and several metabolites have been detected in μg/l in the sewage 
effluent and in surface waters downstream from the WWTP (Heberer, 2002). PPCPs have 
been detected also from groundwater contaminated by landfill leachates and manufacturing 
residues. The most studied substances and their reported occurrence in the natural 
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environment can be divided into the following therapeutic groups (Halling-Sørensen, 1998, 
Heberer, 2002, Kasprzyk-Horden, 2009, Gros, 2009, Jones, 2007, Lindqvist, 2005): 
 Analgetics and Anti-inflammatory drugs (Paracetamol, Aspirin, 
Diclophenac, Ibuprofen) 
 Antiepileptic drugs (Carbamazepine) 
 Stimulants (Caffeine) 
 β-blockers (Atenolol, Propranolol)  
 Antibacterials –ATB (Erythromycin, Tetracycline, Oxytetracycline, 
Sulphamethoxazole, Trimethoprim, Chloramphenicol) 
 Hormones (Oral contraceptives, Testosterone, Estrogen, Estradiol, 
Estrone, 17α-Ethinylestradiol)  
 Antineoplastics (Ifosfamide, Cyclophosphamide) 
 Lipid lowering agents (Clofibric acid, Bezafibrate) 
Substances have been detected (Halling-Sørensen, 1998) from ground water (sulfonamides, 
antineoplastics), river water (ATBs and hormones), ocean water (pharmaceutical dump-
sites), sediments (ATBs) and soil (ATBs, growth promoters and hormones). Research 
shows that the problem is worldwide, similar results on the occurrence in the environment 
have been published in Finland, Sweden, Denmark, Germany, UK, China or USA.   
2.4 Reported effects of PPCPs on non-target species 
A review by Halling-Sørensen et.al (1998) gives an overview of reported effects of PPCPs 
in the environment on non-target organisms. As an example, anti-inflammatory drug 
ibuprofen has a potential antimicrobial activity against Staphylococcus aureus inhibiting 
the growth at concentrations as low as 150μg/ml. ATB streptomycin is affecting the growth 
of several blue-green algae species; furazolidone is proven to be toxic to crustaceans and to 
mosquito larvae Culex pipiens.  
It is generally accepted that the excessive use of ATB in human and veterinary medicine 
causes the development of resistant bacterial strains. Growing resistant bacterial colonies 
have been observed on the medium containing ATB neomycin. Resistant strains of micro-
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organisms are known also for other therapeutic groups, antimalarials or antiretrovirals. 
(Hardman, 2001, Sweetman, 2007). 
Plant species and PPCPs are yet another large unknown area. Persistent compounds and 
pharmaceutical residues possessing biological activity present in irrigation water or in 
organic fertilizer might be accumulated and stored in the agricultural soils. Plants and crops 
could up-take these chemicals unchanged. This could cause adverse effects on the plant 
growth and development as well as causing animal and human re-exposure to these 
xenobiotics. Kumar et.al (2005) tested the plant uptake of chlortetracycline by green onion, 
cabbage and corn. All three plants fertilized by affected manure contained 
chlortetracycline. (Kumar, 2005). Oxytetracycline was found inhibitory for the growth and 
development of roots and shoots of alfalfa (Medicago sativa L.) (Kong, 2007). Fluoxetine 
HCl known better under trade name Prozac
®
 has been detected in all parts of cauliflower 
(Brassicaceae), however no statistically valuable negative effects were recognized 
(Radshaw, 2008). Decline in plant growth was observed by Boxall et. al (2006) for 
phenylbutazone, oxytetracycline and enrofloxacin when lettuce and carrot were exposed. 
Florfenicol and trimethoprim were uptaken by both plants and detected in leaves and roots, 
levamisol was present in the lettuce leaves, diazinon and enrofloxacin were found in the 
carrot root (Boxall, 2006). It has to be pointed out that the pharmaceutical concentration 
tested in mentioned studies was significantly higher than the concentration detected in the 
natural water bodies and soils (Kümmerer, 2004).  
3 Methods of biodegradability analysis 
Estimation of degradation rates is rather challenging process, especially for 
biodegradability since biological processes and living organisms are involved (Struijs, 
1995). Degradation can take place through abiotic processes, such as photochemical 
reactions and hydrolysis, or through biotic processes, i.e. biological degradation. 
Biodegradation is an important process in the WWTP for removal of the substances and 
potential pollutants from the sewage (Kümmerer, 2000). Current knowledge on the WWTP 
removal suggests that many PPCPs (caffeine, ibuprofen or iodinated contrast media) are 
eliminated mainly by biodegradation (Ternes, 2007). Therefore biodegradability was given 
attention in this study. 
Biodegradability refers to the transformation of organic molecules by bacteria, fungi or 
yeast to simple molecules through biological activity. In other words, biodegradability 
expresses the potential of micro-organisms to degrade (mineralize) organic matter or 
organic pollutants. Water and carbon dioxide are the final products of the degradation 
pathways (Murphy, 2002). If all parts of parent compound are reduced to basic inorganic 
elements with or without the presence of oxygen, the parent compound is degradable. 
Biodegradation is often monitored as a degree of mineralization by means of oxygen uptake 
rate (OUR), removal of dissolved organic carbon (DOC) or carbon dioxide evolution. 
With the growing attention to the fate and persistence of organic pollutants in our 
environment during last 40 years, also methods to study biodegradability developed. Large 
number of those methods concentrates on the behavior of organic molecules in the aquatic 
ecosystems (Reuschenbach, 2003).  
3.1 Ready Biodegradability: OECD 301  
Following six methods mentioned in the paragraphs below are permit for screening 
chemicals on their ready biodegradability in aerobic aqueous medium. Mentioned test can 
be also combined; CO2/DOC combination is one example.  
Tests are performed in the dark at constant temperature. At least 70% removal of DOC and 
60% removal of ThOD within 28 days is the pass level of the test for a chemical individual. 
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If pass level is reached, compound is readily biodegradable. If the desired percentage is not 
reached or time period is longer, compound is not readily biodegradable. Ready 
biodegradability tests are often used for quick selection of degradable compounds (Struijs, 
1995). 
All tests mentioned in this paragraph have virtually the same principle and can be 
performed on a wide range of physico-chemical and biological properties (Struijs, 1995). 
Even more, the test mineral medium used in all tests is of the same composition: KH2PO4 
(0,625mM), K2HPO4 (1,249mM), Na2HPO4·2H2O (1,877mM), NH4Cl (0,093mM), CaCl2 
(0,248mM), MgSO4·7H2O (0,0913mM) and FeCl3·6H2O (0,0009mM). (OECD(a), 1992) 
(Reuschenbach, 2003).  
The volatility, solubility, vapor pressure, adsorption and test compound concentration are 
vital values for further selection of appropriate method (OECD(a), 1992).  
3.1.1 DOC die-away test (ISO 7827, OECD 301 A) 
Non-volatile compounds with solubility greater than 100mg/l can be tested by DOC die-
away test. Higher microbial cell concentrations are allowed in the test compared to MITI 
(301 C) mentioned in paragraph 3.1.3. (OECD(a), 1992).  
Known concentration (DOC) of a known compound is measured in inoculated medium for 
28 days without light at 22 ± 2°C. The biodegradation is calculated as a percentage from 
DOC removed compared to original DOC. Another possibility is supplemental chemical 
analysis on the parent compound in the beginning and in the end of the measurement. 
Samples should be taken daily to ensure sufficient amount of data. 
3.1.2 CO2 evolution test (ISO 9439, OECD 310 B) - Modified Sturm Test 
Biodegradability of non-volatile compounds, where the formula, carbon content and purity 
are known can be tested by CO2 evolution test. Test is suitable also for poorly soluble and 
adsorbing compounds. Test substance in inoculated medium is the sole source of carbon in 
the system. CO2 produced by the microbial activity is trapped by NaOH and determined by 
titration of the residual hydroxide. Biodegradability is presented as a percentage of ThCO2. 
Sampling should take place every second day during the first 10 days and every fifth day 
for the rest of the measuring period (OECD(a), 1992). 
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3.1.3 MITI (OECD 301 C) 
Formula and purity of the tested substance should be known in order to calculate theoretical 
oxygen demand (ThOD) and perform the measurement. MITI test can be used also for 
insoluble and volatile compounds. The principle of the MITI test is automatic measurement 
of the oxygen uptake in an enclosed respirometer. Values of the oxygen uptake expressed 
in mg/l are compared to the original ThOD. The result of the comparison is the percentage 
of biodegradation (OECD(a), 1992).  
3.1.4 Closed bottle test (ISO 10707, OECD 301 D) 
As in the previous test also closed bottle test CBT can be used for insoluble or volatile 
compounds. Small number of microorganism from a mixed population is added to the 
inoculated media with the tested substance. The mixture is kept in full closed containers for 
desired period of time. Biodegradability is expressed by comparison of consumed oxygen 
during the degradation to the original ThOD (OECD(a), 1992). 
3.1.5 Modified OECD screening (OECD 301 E) 
Substances with solubility over 100mg/l and non-volatile substances can be tested by 
modified OECD screening method. The method is similar to DOC die-away test, however 
compared to 301 A lower concentration of the microorganisms is allowed (OECD(a), 
1992). 
3.1.6 Manometric respirometry test (ISO 9408, OECD 301 F) 
By manometric respirometry test, insoluble or volatile compounds can be assessed. Higher 
substance concentrations (100mg/l) compared to the previous methods can be tested by 
manometric respirometry. Biodegradability is determined by the oxygen consumption or by 
CO2 evolution. Oxygen consumption is determined by measuring the amount of oxygen 
that has to be produced and added to the system to maintain the same pressure or constant 
gas volume. CO2 is trapped in hydroxide sorbent and determined by titration (OECD(a), 
1992).  
The principle of manometric respirometry is used in the automated systems for Biological 
Oxygen Demand determination (BOD), such as OxiTop® or Sampromat® mentioned later 
in this chapter. 
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3.1.7 Combined CO2/DOC test 
The combined CO2 and DOC test is a reliable test for aerobic biodegradability 
determination in aquatic ecosystems (Strotmann, 1995). The new test combines the study of 
two parameters for biodegradability analysis, the removal of dissolved oxygen (DOC) and 
carbon dioxide production. The test provides sufficient reliability of the obtained results 
and larger amount of data compared to CO2 evolution test, DOC die-away test or 
respiratory test performed alone. 
3.2 Inherent Biodegradability: OECD 302 
The original test method was adopted in 1981 as OECD 302 B method for testing inherent 
biodegradability (OECD(b), 1992). The original method was merged with tests developed 
by EMPA and final change was implemented in 1992 concerning the mineral medium 
composition. The new composition is identical with the OECD 301 guideline. 
3.2.1 Semi-continuous activated sludge test (SCAS): OECD 302 A 
Semi-continuous activated sludge test (ISO 9887, OECD 302 A) uses activated sludge as 
inoculum as following Zahn-Wellens test. (Pagga, 1997) Both methods have high 
degradability potential and can be used to determine the potential inherent biodegradability.  
3.2.2 Zahn-Wellens/EMPA: OECD 302 B 
The method is similar to ISO 9888 standard to measure inherent biodegradability. The 
mixture of the mineral medium, test substance and rather large amount of activated sludge 
is aerated at 20 - 25ºC in the dark for 28 days. The biodegradation is monitored by DOC 
determination in the filtered samples on daily bases. 
The solubility, vapor pressure and structure of the test substance are necessary properties to 
be known. Substances that are non-volatile, do not adsorb significantly, and are not lost by 
foaming can be tested in the inherent biodegradability test. Zahn-Wellens test is usually 
applied after one of the tests on ready biodegradability (OECD 301), the inhibition and 
physical properties are therefore in many cases already known. The biodegradation must 
reach 70% of DOC removal within 14 days.  
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3.2.3 Modified Zahn-Wellens test 
Modified Zahn-Wellens test enables continuous and parallel determination of oxygen 
consumption and CO2 production (Norr, 2001). The modification is using inexpensive 
laboratory equipment designed as a closed system apparatus. Oxygen consumption is 
measured by the pressure change measurement and the CO2 production is determined by 
the conductivity measurement. The system allows the inherent biodegradability 
measurement for poorly soluble compounds and for adsorbing or volatile substances. The 
measuring signals are transmitted to PC and stored automatically, which allows the 
continuous and parallel measurement of the parameters for biodegradability determination. 
The setting parameters of the measurement (test concentration, temperature, inoculums 
concentration, test medium composition, pH and duration) are as the parameters described 
for Zahn-Wellens test.    
3.3 Automated determination of biodegradability 
With the development of PC technology, commercially available automated systems to 
measure biodegradability appeared. Both presented systems, Sapromat and OxiTop-C are 
based on the manometric respirometry measuring principle in a Closed Bottle System 
(CBS) where Biological Oxygen Demand (BOD) is determined. 
The value of BOD expressed in mg/l shows the amount of oxygen required to decompose 
the organic matter present in water sample by aerobic digestion. BOD can be used as a 
parameter for expressing the water quality in the wastewater management and assessing the 
behavior of the treatment systems (Mara, 2003). BOD can be also used to describe the 
organic material strength of influents and effluents and to monitor environmental 
pollutants. (Roppola, 2009)  
For the assessment of pharmaceutical behavior in the WWTP, BOD can be used to evaluate 
the efficiency of substance removal from wastewater during the biological treatment 
operations.  Furthermore BOD measurement can be used to study the effects on 
microorganisms, the substance toxicity or inhibition.  
Biodegradation is an important part of the WWTP removal operations. While great number 
of pharmaceuticals is proven to poses toxic or inhibitory effects on the biotic populations of 
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WWTP the PPCPs can cause decrease in removal efficiency of PPCPs as well as the 
removal of other organic matter from the wastewater and causing consequently secondary 
organic pollution. (Roppola, 2009) 
BOD tests for water quality determination are performed under strictly defined conditions 
for the time period of 5 or 7 days. BOD measurements applied to the ready biodegradability 
analysis of pharmaceuticals have a prolonged time period of 28 days (Mara, 2003, 
OECD(a), 1992). 
3.3.1 OxiTop ® – C  
OxiTop-C is a BOD self-measuring mercury free system applicable also for respiration or 
biogas determination tests. The principle is based on the pressure measurement in a closed 
bottle system. CO2 produced by microbial activity is absorbed by NaOH creating vacuum. 
The pressure difference can be read by the operating unit and is presented as mg/l BOD.  
 
Figure 2 Data presentation by OxiTop measuring system, (WTW, 2009) 
Figure 2 shows the example of data presentation by OxiTop measuring system. The curve 
of diluted sample shows the ideal biodegradation curve of a readily biodegradable 
substance. Inhibited curve is typical for substances inhibiting the metabolism of 
microorganisms and result in slow increase of oxygen consumption. Disinfected sample 
curve does not show any BOD value and is typical for toxic substances; microorganisms 
are killed shortly after the exposure to the chemical hence no oxygen is consumed. 
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OxiTop - C measurement simulates biological processes of WWTP. Any disturbance in the 
simulated process or low BOD value points on possible disturbance in the WWTP 
processes, inhibition of bacteria, toxic effects and potentially persistant compounds. 
3.3.2 Sapromat ® E 
Sapromat BOD measuring system consists of 12 independent measuring vessels (500ml) 
with CO2 traps containing soda lime. Each vessel is placed into a water bath at constant 
temperature and connected to manometer and an electrochemical oxygen production unit, 
see Figure 3. During the biodegradation, oxygen from the system is consumed creating sub-
pressure which induces the manometer and the electrochemical unit producing oxygen until 
the pressure is even. The oxygen consumption (BOD) values are controlled continuously, 
transferred to a computer and used for the biodegradability calculation as a comparison of 
the ThOD and BOD (Reuschenbach, 2003, H+P, 2010).  
 
Figure 3 Sapromat ® E measuring system (H+P, 2010) with the water bath and PC measuring unit 
3.4 Other available methods 
Activated sludge simulation test (ISO 11733, OECD 303) for wastewater plants and Low 
test concentrations test (ISO 14592) may be used to establish kinetic biodegradability 
parameters, which explain far more details about the biodegradation processes (Pagga, 
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1997). Test at low test concentrations is often used to simulate biodegradation in natural 
lakes and ponds. Anaerobic biodegradability test (ISO 11734) simulates the environment in 
digesters of WWTP. Marine degradation test (OECD 306) is a special aquatic test for 
marine environments. Aerobic composting test (ISO 14855) is a method simulating 
composting facility and is used to study biodegradability of polymers (Pagga, 2001). 
Only one internationally harmonized method is available for degradation in soils or in 
sediments. Soil test (OECD 304) requires the 
14
C-labelled material and measures the 
14
C-
labelled carbon dioxide produced (Pagga, 1997).  
3.5 Comparison of the test methods 
For the ready biodegradation studies most commonly used methods are the DOC die-away 
test, the CO2 evolution test and manometric respirometry. The limiting parameters for the 
tests application are the water solubility, volatility of the compound and the toxicity to the 
used inoculum. In OECD 301 tests, the test substance has to be the sole source of carbon. 
Unknown impurities cannot be calculated to the original ThOD. If unknown impurities are 
present, final comparison of ThOD/BOD will not return true biodegradability value. 
Since it is not possible to distinguish between real biodegradation and abiotic degradation 
processes, all tests for ready and inherent biodegradability based on DOC measurements 
are limited. (Pagga, 1997). It is also difficult to distinguish between the oxidized part of the 
substance and the part incorporated to the biomass. Furthermore, only bacteria are used in 
the aquatic settings. Apart from bacteria, fungi and yeast contribute considerably to the 
degradation process in compost or in soils; however their growth is limited in the aquatic 
environment (Pagga, 2001). All tests performed in the aquatic environment have therefore 
lower degradation values compared to aerobic composting test. A great advantage of the 
classical biodegradation methods is the inexpensive apparatus using conventional 
laboratory glass. 
Sapromat has a low maintenance, and large mode of application for the BOD 
measurements. Sapromat measuring system provides large amount of data accessible on 
PC. With the control unit, measuring system can be left for several days for independent 
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operation. (H+P, 2010) The main advantage of the Sapromat system is the possibility to 
extend nearly infinitely the measurement period. (Reuschenbach, 2003) 
The advantages of OxiTop-C system are simple operation and compact design, 
controllability and large measuring range, up to 400 000 mg/l BOD. The system enables 
simultaneous and grouped start, management, storage and tracking of 100 measuring heads. 
The reliable, accurate data is presented graphically and can be easily transported to PC. 
OxiTop-C system can operate individually for the whole period of measurement. The data 
can be called up at any point of the measurement for test control (WTW, 2009).  
When comparing OxiTop-C and Sapromat systems, the difference in the degradation value 
is negligible (bellow 10%), lag phases are quite consistent and the degradation rate is not 
consistently greater or smaller for one system (Reuschenbach, 2003). A common 
disadvantage for both automated systems is expensive apparatus. 
Reuschenbach et.al. presented a study comparing the classical biodegradability tests with 
the new automated systems using aniline as a reference substance. Test methods were 
Zahn-Wellens test for inherent biodegradability, DOC die-away test, CO2 evolution test, 
OxiTop-C and Sapromat both systems being based on the method of manometric 
respirometry. Degradation rate was again comparable for both respirometry systems, 
Sapromat and OxiTop. DOC die-away test had the highest degradation rate, at the same 
time CO2 evolution test the lowest. The lag periods were the longest for Sapromat, but 
comparable for OxiTop, DOC die-away and CO2 evolution test. Last three mentioned tests 
also showed greater final degradation percentage compared to Sapromat system 
(Reuschenbach, 2003).  
 
4 Pharmaceuticals 
In the following paragraphs the pharmaceuticals selected for the biodegradability analysis 
are introduced. Separate paragraphs are organized based on the therapeutic group 4.1, 
toxicity 4.2, physico-chemical properties 4.3, and on the biodegradability and wastewater 
removal information 4.4. 
4.1 Therapeutic group 
Chemical species concerned in the study were divided into groups according to their 
therapeutic application. The therapeutic application is in several cases connected with the 
possible target organism; virus, bacteria, protozoa etc. The main reason for this decision 
was the following experimental section of the work, where the effect on microorganisms 
has a crucial role on the BOD value and the final biodegradation rate.  
The mentioned groups are antiviral chemical species affecting viruses 4.1.1, antimicrobial 
pharmaceuticals affecting prokaryotic cells such as bacteria – antibiotics (ATB) 4.1.2, and 
antimicrobial pharmaceuticals affecting eukaryotic cells such as protozoal organisms 4.1.3, 
helminths 4.1.4 and fungi 4.1.6.  
Following groups include pharmaceuticals affecting functions and systems of higher 
organisms, for example anti-inflammatory drugs 4.1.5, antiulceratives and antiepileptics 0. 
(Tortora, 2007) 
4.1.1 Antiviral pharmaceuticals 
Viruses are intracellular parasites that are using metabolism of the hosting cell and posing a 
difficult problem for the choice of efficient chemotherapy. Selective toxicity for the virus is 
harder to achieve compared to higher organisms. (Bennett, 2003) 
The main mechanisms of action are the inhibition of the adsorption to the hosting cell, 
repression of the viral nucleic acid (NA) and the interference with the transcription and 
translation of the viral NA. (Bednář, 1999)  
The most common diseases treated by the antiviral pharmaceuticals are chickenpox 
(Varicella-zoster), Herpes simplex virus, HIV and Hepatitis B, C, or D. (Bennett, 2003) 
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Because of the location and the lacking information, three antiretroviral pharmaceuticals for 
treating HIV infections were selected, see Table 1.  
HIV is the causative agent for acquired immunodeficiency syndrome (AIDS). (Sweetman, 
2007) Two subtypes of the virus have been recognized, HIV-1 occurring worldwide and 
HIV-2 typical for West Africa. HIV uses the CD4 receptors to enter T-lymphocytes and 
monocytes/macrophages where the viral RNA is translated to DNA by reverse transcriptase 
enzymatic catalysis. Transcribed viral DNA is then inserted to the genome of the host cell. 
Viral replication results in constant depletion of T-lymphocytes and reduction in the 
immune response of the host organism.  
Table 1 Antiretroviral pharmaceuticals 
 
Chemical 
CAS # Formula 
Mr 
(g/mol) 
Therapeutic 
use 
Lamivudine 134678-17-4 
C8H11N3O3S                         
229,256 
Antiviral 
(HIV, Hepatitis 
B) 
Nevirapine (viramune) 129618-40-2 
 
C15H14N4O                            
266,298 
Antiviral  
(HIV) 
Zidovudine 30516-87-1 
 
C10H13N5O4                         
267,241 
Antiviral  
(HIV) 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
Lamivudine is a white powder soluble in water exhibiting polymorphism. Lamivudine is in 
the cells converted to active antiviral triphosphate (Sweetman, 2007). Triphosphate stops 
DNA synthesis of retroviruses through competitive inhibition of reverse transcriptase and 
the incorporation to the viral DNA. Lamivudine is rapidly absorbed after oral dose. The 
bioavailability is between 80 and 87%. Lamivudine is metabolized intracellularly, hepatic 
metabolism is low and clearance takes place mainly by renal excretion of the unchanged 
compound. Lamivudine is a potent inhibitor of HIV-1 and HIV-2, including strains 
resistant to zidovudine. Lamivudine is also one of the promising antivirals used in the 
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treatment of hepatitis B infections. However, resistance against lamivudine has been 
reported for HIV and hepatitis B virus. 
Nevirapine is white powder practically insoluble in water and sparingly soluble in 
dichlormethane and methyl alcohol. Nevirapine is metabolized by cytochrome P450 
isoenzymes and readily absorbed after oral doses. The bioavailability of nevirapine is 
greater than 90%. Nevirapine is mainly excreted in the urine as glucuronide conjugates of 
hydroxylated metabolites (Sweetman, 2007).  
Zidovudine is white or brownish powder soluble in water and dehydrated alcohol, which 
should be protected from light; photodegradation of the drug is expected. After absorption 
by organism, zidovudine is metabolized to triphosphate which inhibits the synthesis of 
retroviral DNA. Zidovudine is rapidly absorbed by gastrointestinal tract (GIT) and 
undergoes first-pass hepatic transformation (bioavailability 60-70%). After intercellular 
metabolic change to triphosphate it is metabolized by liver to inactive glucuronide. 
Zidovudine is excreted via urine as metabolite and parent compound (Sweetman, 2007). It 
has been proven zidovudine possesses activity against Epstein-Barr virus and Gram-
negative bacteria. Long-term monotherapy causes formation of zidovudine-resistive strains 
of HIV and therefore it is used in combination with other pharmaceuticals. Zidovudine 
shows haematologic toxicity and is reported to be carcinogenous in rodents. 
4.1.2 Antibacterial pharmaceuticals 
This paragraph is dedicated to the pharmaceutical species treating bacterial infections, i.e. 
infections caused by simple organisms with a prokaryotic cell structure. These chemical 
species are often referred to as antibacterials or antibiotics (Sweetman, 2007). 
Bacteriostatics and disinfectants are often mentioned in the same therapeutic group even 
though the mechanism of action on the target organism is different.  
The very diverse group of antibacterial pharmaceuticals is often divided into subgroups 
according to their chemical structure, their mode of activity or according to the spectrum of 
antimicrobial activity. Mentioned objectives are often interconnected and similarity in the 
chemical structure results in the similarity of microbial activity. Most commonly referred 
groups are aminoglycosides, antimycobacterials, cefalosporines and β-lactams, 
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chloramphenicols, glycopeptides, macrolides, quinolones, sulfonamides and tetracyclines 
(Sweetman, 2007). 
The mechanism of effect can be classified as (Bennett, 2003):  
 Inhibition of cell wall synthesis (β-lactams – penicillin and cephalosporin) 
 Inhibition of the protein synthesis (aminoglycosides, tetracycline, 
macrolides) 
 Inhibition of the NA synthesis (sulphonamides, quinolones) 
Table 2 Antibacterial pharmaceuticals 
Chemical CAS # Formula 
Mr 
(g/mol) 
Therapeutic 
use 
Ethambutol HCl 
(antimycobacterials) 
1070-11-7 
 
C10H24N2O2. 2HCL            
277,230 
Antibacterial  
(Mycobacteriu
m tuberculosis) 
Metronidazole Benzoate 
(imidazols) 
13182-89-3 
                                      
C13H13N3O4                  
275,300 
Antibacterial, 
antiprotozoal 
(Giardia 
lamblia, 
Trichomonas) 
Ofloxacin 
(quinolones) 
82419-36-1 
C18H20FN3O4                        
361,368 
Antibacterial 
(Chlamydia, M. 
tuberculosis, M. 
leprae) 
Isoniazid 54-85-3 
 
C6H7N3O                                
137,1393 
Antibacterial 
Antitubercular 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
For the purpose of the study, four antibacterial pharmaceuticals were chosen ethambutol, 
ofloxacin, metronidazole benzoate and isoniazid. Details about the antibacterial group, 
chemical formula and structure, the molecular weight and the therapeutic group can be 
found from Table 2. 
Ethambutol hydrochloride is a white crystalline powder freely soluble in water and alcohol. 
2% solution is slightly acidic with pH 3,7 – 4,0 and should be stored in air-tight containers, 
short half-life and fast degradation is expected. Ethambutol is absorbed by GIT by 80% of 
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the oral dose. Ethambutol is partially metabolized in the liver forming aldehyde and 
dicarboxylic acid derivates. These metabolites are inactive and excreted in the urine, most 
of the drug appears as a parent compound in the urine within 24 hours (8 – 15% is present 
as inactive metabolites) and 20% of the dose is excreted in feces (Sweetman, 2007). 
Ethambutol is used to treat Mycobacterium infections, however when used alone resistant 
strains of M.tuberculosis are produced. 
Metronidazole benzoate is a white crystalline powder or flakes insoluble in water, slightly 
soluble in alcohol and soluble in acetone. Photodegradation is expected, metronidazole b. 
should be therefore protected from light. Metronidazole is almost completely absorbed after 
oral application. Accumulation in the organism may occur after multiple doses. 
Metronidazole benzoate is hydrolyzed to metronidazole in GIT in order to be absorbed. 
Metronidazole is metabolized in the liver by side-chain oxidation and glucuronide 
formation. The majority of metronidazole is excreted in urine mainly as metabolites (1-(2-
hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-acetic 
acid), small amount appears in feces (Sweetman, 2007). Metronidazole is carcinogenic in 
bacterial assays and even though it has been classified as carcinogenic for animals, the 
carcinogenity for humans is ambiguous. Metronidazole is prescribed against several 
protozoal microorganisms (Blastocystis hominis, Giardia intestinalis and G.lamblia, 
Trichomonas vaginalis), and is also active antibacterial (Bacteroides, Clostridium spp., 
Helicobacter pylori). Resistance to metronidazole and to other imidazole antibacterials has 
been reported. 
Ofloxacin is a yellow crystalline powder, soluble in water and in methyl alcohol, soluble in 
dichloromethane and in glacial acetic acid. Ofloxacin should be stored in air-tight 
containers and protected from light. Ofloxacin is rapidly absorbed from GIT (~100%), up 
to 80% of the dose is excreted by tubular secretion and glomerular filtration in kidneys 
resulting in high urinary concentrations (less than 5% is excreted as metabolites). 4-8% 
may be excreted in feces (Sweetman, 2007). Ofloxacin belonging to the fluoroquinolone 
group is more active compared to ciprofloxacin (Chlamydia trachomatis, Mycobacterium 
leprae and M.tuberculosis). S-(-) isomer of ofloxacin, levofloxacin has twice the activity of 
ofloxacin. Resistance has been reported for strains of Neisseria gonorrhoeae. 
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Isoniazid is a white powder soluble in water and sparingly soluble in alcohol unstable when 
exposed to air and light. 5% solution has pH between 6,0 to 8,0. Primary metabolic route is 
the acetylation to acetylisoniazid in liver and small intestine. Acetylisoniazid is hydrolyzed 
to isonicotinic acid and monoacetylhydrazine. Isonicotinic acid is conjugated with glycine 
to isonicotinuric acid, monoacetylhydrazine is acetylated do diacetylhydrazine. Un-
metabolized isoniazid is hydrolyzed to hydrazones. Metabolites do not poses 
tuberculostatic activity and are less toxic compared to the parent compound. Over 75% of 
the dose is excreted via urine mainly as metabolites. Isoniazid is highly active against M. 
tuberculosis and may be also used to treat other mycobacterial infections (M. kansasii). 
(Sweetman, 2007) Resistance against isoniazid develops rapidly when used alone in the 
clinical infection treatment. 
4.1.3 Antimalarial pharmaceuticals 
Pharmaceuticals described in this paragraph and Table 3 are chemical species affecting 
parasitic infections caused by Plasmodium protozoa. Plasmodium species cause malaria, a 
serious and potentially fatal disease.  
Amodiaquine is odorless powder practically insoluble in water and slightly soluble in 
alcohol which should be stored in air tight containers. Amodiaquine hydrochloride is a 
crystalline powder soluble in water and alcohol, and slightly soluble in chloroform. 
Amodiaquine is readily absorbed from GIT and metabolized in the liver to the active 
compound leaving only very small amount of amodiaquine unchanged in the excreted 
urine. The half life of amodiaquine in the blood plasma is long and the parent compound 
with the active metabolite can be detected in urine several months after the administration. 
Quinine sulfate is a water soluble white powder that should be protected from light. 
Quinine is rapidly and almost completely absorbed from GIT. After extensive hepatic 
metabolic transformation, quinine is excreted mainly in urine. (Sweetman, 2007) 
 Pyrimethamine is white crystalline powder practically insoluble in water, sparingly soluble 
in alcohol and unstable exposed to light. Pyrimethamine is after absorption from GIT 
concentrated in liver, kidneys, lungs and spleen. Pyrimethamine is excreted by kidney, 
metabolites are detected in urine. Pyrimethamine is used in the treatment of malaria and 
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toxoplasmosis. The antimalarial activity is through the inhibition of the NA synthesis of the 
malaria parasite. Main activity is detected against Plasmodium falciparum and P.vivax. 
Because of the resistant strains development, pyrimethamine is currently recommended 
mainly for the treatment of toxoplasmosis.  
Table 3 Antimalarial pharmaceuticals 
Chemical CAS # Formula and structure 
Mr 
(g/mol) 
Therapeutic 
use 
Amodiaquine HCl 69-44-3 
 
C20H22ClN3O (2HCl)          
464,800 
Antimalarial,  
Amebicide 
Quinine Sulfate 
 
804-63-7 
 
                        
                                     
2(C20H24N2O2)
.H2SO4       
 
746,910 
 
Antimalarial,  
Analgetic 
 
Pyrimethamine 
 
58-14-0 
C12H13ClN4                           
248,711 
 
Antimalarial 
(toxoplasmosis) 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
 
4.1.4 Anthelmintic pharmaceuticals 
Helminth infections are one of the most common human infections around the world, large 
proportion of the population is however affected in the tropical regions. In developing 
countries, helminth infections pose a large threat to the public health and contribute to other 
problems and diseases (malnutrition, pneumonia and anemia). The eradication of helminth 
infection does not depend only on the use and availability of chemotherapeutics, but also on 
the hygiene, proper food preparation and satisfactory sanitation systems with 
uncontaminated water supply (Sweetman, 2007). 
Helminths are a very diverse group of eukaryotic parasites differing with the life cycle, 
structure, development and physiology, location within the host and their sensitivity to 
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chemotherapeutics (Brunton, 2006). Worms pathogenic for humans are nematodes 
(roundworms), trematodes (flatworms) and cestodes (tapeworms).  
Anthelmintics (Table 4) are pharmaceuticals treating infections caused by parasitic worms 
either by expelling the worms from the GIT or systematically by eradicating the adult 
worms and the developmental forms (Bennett, 2003). 
Table 4 Anthelmintic pharmaceuticals 
Chemical CAS # Formula and structure 
Mr 
(g/mol) 
Therapeutic 
use 
Levamisole HCL 16595-80-5 
C11H12N2S.HCl                     
240,750 
Anthelmintic  
(Nematodes),  
Immuno-
modulans 
Mebendazole 
(benzimidazol carbamate 
derivate) 
31431-39-7 
C16H13N3O3                          
295,293 
Anthelmintic  
(Nematodes) 
Piperazine Citrate 144-29-6 
 
                                      
2(C6H8O7)
.3(C4H10N2)
.H2O                                       
642,700 
Anthelmintic 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
Levamisole hydrochloride is a white crystalline powder freely soluble in water unstable 
exposed to light. 5% water solution has pH from 3,0 to 4,5. Levamisole is active against 
intestinal nematodes in particular ascariasis and hookworm infections. The sensitive worms 
are paralyzed and excreted from the intestines (Sweetman, 2007). 
Mebendazole is a white powder showing polymorphism, practically insoluble in water, 
alcohol or dichlormethane, unstable exposed to light. Mebendazole is active against most 
nematodes, against some larval stages and ova. It destroys the cytoplasmic microtubules in 
the worm cells causing the death within several days (Sweetman, 2007). 
Piperazine citrate is white granular powder, soluble in water and practically insoluble in 
alcohol. Piperazine is absorbed from GIT and excreted partly as metabolites via urine. 
Prescription prevails against intestinal nematodes Ascaris and Enterobius (Sweetman, 
2007).  
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4.1.5 Anti-inflammatory pharmaceuticals 
Anti-inflammatory pharmaceuticals are used in relief of inflammation, pain or fever. They 
are often grouped as salicylates (aspirin), anti-rheumatic drugs, gold compounds, non-
steroidal anti-inflammatory drugs (diclofenac), opioid analgesics and para-aminophenols 
(paracetamol). Aspirin has been chosen for the study because of wide world use. 
Table 5 Anti-inflammatory pharmaceuticals 
Chemical CAS # Formula 
Mr 
(g/mol) 
Therapeutic 
use 
Aspirin (Acetylsalicylic acid) 
(Salicylate NSAID) 
50-78-2 
 
C9H8O4                                 
180,157 
Anti-
inflammatory, 
Anticoagulant 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
Aspirin (Table 5) is a white crystalline powder, slightly soluble in water and freely soluble 
in alcohol. Aspirin is readily absorbed in non- ionized form from GIT, stomach and 
intestine. Aspirin acts as inhibitor of cyclo-oxygenase which directly inhibits the 
production of prostaglandins and tromboxanes. Elimination is by hepatic metabolism to 
salicyluric acid, salicyl phenolic glucuronide, salicylic acyl glucuronide, gentisic and 
gentisuric acid. With the increasing therapeutic dose and increasing alkalinity of the urine 
also unchanged parent compound is excreted.  
4.1.6 Antifungal pharmaceuticals 
Antifungal pharmaceuticals are preparations used in the treatment and prophylaxis of 
fungal infections. Most fungi pathogenic in humans can be classified as yeasts and moulds 
and are saprophytic in nature (Sweetman, 2007). They cause infections when airborne 
spores reach lungs, skin or eye. Example of pathogenic fungi is Aspergillus, Candida or 
Pneumocystis.   
Ketoconazole (Table 6) is a white powder, practically insoluble in water, sparingly soluble 
in alcohol and freely soluble in dichlormethane, unstable exposed to light. Ketoconazole is 
an imidazole derivate that inhibits ergosterol synthesis and alters the permeability of the 
fungal cell membrane. It is metabolized by liver and excreted as inactive metabolites in 
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feces. Ketoconazole has wide spectrum of antifungal activity and resistance to this 
chemotherapeutic is rare. Ketoconazole is proven to be hepatotoxic.  
Table 6 Antifungal pharmaceuticals 
Chemical CAS # Formula 
Mr 
(g/mol) 
Therapeutic 
use 
Ketoconazole 
(Imidazole derivates) 
65277-42-1 
C26H28Cl2N4O4                   
531,431 
Antifungal for 
immune-
suppresed 
patients 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
4.1.7 Other therapeutic use and PCPs  
In this paragraph, pharmaceuticals with effect on higher organism and its separate systems 
are discussed. The groups of pharmaceuticals are very large and diverse, therefore only the 
mechanism of action of the chosen chemical species will be described in more detail, see 
Table 7.  
Pantoprazole is a proton pump inhibitor which can be prescribed in gastro-oesophageal 
reflux disease, peptic ulcer diseases and pathological hypersecretory states. Pantoprazole is 
metabolized in liver by cytochrome P450 isoenzyme to desmethylpantoprazole and 
excreted in urine. 
Hydrocortisone acetate is a white crystalline powder practically insoluble in water, unstable 
exposed to light. Hydrocortisone is absorbed by GIT and metabolized in the liver to 
hydrogenated and degraded forms (tetrahydrocortisone and tetrahydrocortisole). 
Metabolites are excreted via urine conjugated to glucuronides (Sweetman, 2007). 
Carbamazepine is a white crystalline powder that exhibits polymorphism and is unstable 
exposed to air. It is slightly soluble in water, sparingly in alcohol and acetone, freely 
soluble in dichlormethane. Carbamazepine is a dibenzazepine derivate with antiepileptic 
and psychotropic properties. It is used to treat epilepsy, trigeminal neuralgia and in 
prophylaxis of bipolar disorder. Carbamazepine is irregularly and slowly absorbed from 
GIT and extensively metabolized by liver by cytochrome P450 isoenzymes CYP3A4 and 
CYP2C8. Carbamazepine is excreted mainly in urine in the form of metabolites 
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(carbamazepine-10,11-epoxide), which keeps the original activity of the parent compound 
(Sweetman, 2007).  
Table 7 Antiulcerative, antiepileptic and glucocorticoid pharmaceuticals 
Chemical CAS # Formula 
Mr 
(g/mol) 
Therapeutic 
use 
Pantoprazole 102625-70-7 
      
                   
C16H15F2N3O4S   
383,370 Antiulcerative 
Hydrocortisone Acetate 50-03-3 
  
                               
C23H32O6                                                         
404,500 Glucocorticoid 
Carbamazepine 298-46-4 
 
C15H12N2O                           
236,2686 
Antiepileptic, 
analgesic 
Dextrose Monohydrate 5996-10-1 
 
C6H12O6.H20                 
198,170 Additive 
Reference: (DrugBank. Wishart, 2010, Merck, 2006, Sweetman, 2007, ChemBlink, 2007). 
Dextrose monohydrate and Carbamazepine were chosen as compounds of comparison with 
the source literature, dextrose as a readily biodegradable, non-toxic non-inhibitory 
compound while Carbamazepine as a non-biodegradable persistent compound according to 
source information (Kasprzyk-Horden, 2009, Joss, 2005, Zhang, 2008, Ternes, 1998). 
4.2 Toxicity   
In the following the toxicity values were collected. Oral Acute dose LD50 for rat (mouse) is 
the most common available value for all pharmaceutical species, Table 8 (p.41).  
Effective concentration EC50 then expresses the toxicity to Daphnia magna, algae or sludge 
bacteria. EC50 value used to express the environmental toxicity is another example next to 
biodegradability of incomplete available information. Existing studies concentrate on the 
research of the medical treatment and effects on target organisms while the knowledge on 
Pharmaceuticals  40/73 
the effects of individual pharmaceuticals on the non-target organisms is missing. As an 
example, amodiaquine is largely studied on the toxicity effects towards Plasmodium 
falciparum (Brasseur, 1995), environmental toxicity is not available.  
The EU directive 93/67/EEC classifies chemicals according to their EC50 value to following 
classes: very toxic to aquatic organisms (<1mg/l), toxic to aquatic organisms (1-10mg/l), 
and harmful to aquatic organisms (10-100mg/l). Chemicals with EC50 value over 100mg/l 
are not classified. (CEC, 1996)  
4.3 Physico-chemical properties 
Table 9 (p.42) presents the collected values describing the physico-chemical properties. pKa 
value describes the tendency of molecules or ions to dissociate in water. Octanol-water 
partitioning coefficient (Kow) is a ratio of chemical concentration in octanol and in water at 
defined conditions. Kow is used to determine the fate of chemicals in the environment and 
possible bioaccumulation or adsorption to solids (Morganwalp, 2010). 
4.4 Removal of pharmaceuticals and Biodegradability 
Table 10 (p.43) presents current available information on the removal efficiency (%) of 
selected pharmaceuticals during WWTP processes and the biodegradability (%). As 
mentioned before, the information on the selected pharmaceuticals is scarce. Bioavailability 
(%) is a value describing the availability of therapeutics to the receiving organism. Half life 
value mentioned in the Table 10, is the half life of the therapeutics in the blood plasma. 
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Table 8 Toxicity of pharmaceuticals: Acute Oral dose LD50 to rat (r) or a mouse (m) and effective 
concentration EC50 to Daphnids, algae and activated sludge bacteria 
Toxicity of pharmaceuticals: Acute Oral LD50 for rat (r) or mouse (m), Effective concentration for 
Daphnids and Algae 
Chemical 
AO LD50 
(mg/kg) 
note Reference 
EC50 (mg/l) 
Reference Daphnids 
(mg/l) 
Algae 
(mg/l) 
Sludge b. 
(mg/l) 
Amodiaquine HCl 550 m a 
 
 102,82 (Basnyat, 2010) 
Aspirin (Acetylsalicylic acid) 200 r d 8858,00 61,00 
 
50,43 
(Sanderson, 2003) 
(Basnyat, 2010) 
Carbamazepine  4025 r 
(Merck, 
2001) 
76,30 85,00  (Huschek, 2004)  
Dextrose Monohydrate 25800 r d 
 
    
Ethambutol HCl 6800 r d 
 
    
Hydrocortisone Acetate 2300 
IPR 
m 
d 
 
    
Isoniazid 160 r d 23,00 25,00  (Sanderson, 2009) 
Ketoconazole 86 r a 
 
    
Lamivudine >2000 r d >1000   (Sanderson, 2009) 
Levamisole HCL 180 r d 
 
 15,02 (Basnyat, 2010) 
Mebendazole 620 m a 
 
    
Metronidazole Benzoate 330 r d 
 
12,50  (Sanderson, 2009) 
Nevirapine (viramune) 400 r d 
 
    
Ofloxacin USP 3590 r d 
31,75 
17,41 
 
1,44 
 
(Isidori, 2005), 
(Sanderson, 2009) 
Pantoprazole 1000 m d 
 
    
Piperazine Citrate 11200 r d 
 
    
Pyrimethamine 440 r d 4,80 20,00  (Sanderson, 2009) 
Quinine Sulfate B.P 620 r d NA NA 
 
-19,00 
(Sanderson, 2009) 
(Basnyat, 2010) 
Zidovudine 3084 r d >100  
 
886,80 
(Sanderson, 2009)  
(Basnyat, 2010) 
Reference: a - DrugBank. Wishart, 2010, d - MSDS 
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Table 9 Physico-chemical properties of pharmaceuticals 
Physico-chemical properties of selected pharmaceuticals 
Chemical pKa 
logP 
(hydrofobicity) 
log Kow Reference Photodegradability 
Amodiaquine HCl na 3,70 a   No b 
Aspirin (Acetylsalicylic acid) 3,49 a 1,40 a 1,13 (Sanderson, 2003) No b 
Carbamazepine Neutral 2,3 a 2,25 (Sanderson, 2003) No b 
Dextrose Monohydrate na  na na  Na 
Ethambutol HCl na -0.3 a   No b 
Hydrocortisone Acetate na  0,5 a   Yes b 
Isoniazid 1,82 a -0,8 a 
0,97 
-0,81 
(Sanderson, 2003), 
(Sanderson, 2009) 
Yes b 
Ketoconazole na 4,0 a   Yes b 
Lamivudine na -1,40 a na  Yes b 
Levamisole HCL na 2,30 a   Yes b 
Mebendazole na 2,80 a   Yes b 
Metronidazole Benzoate 2,40 a -0,1 a -0,1 (Sanderson, 2009) Yes b 
Nevirapine (viramune) na 2,50 a   No b 
Ofloxacin USP 7,90 a 2,10 a 0 (Sanderson, 2009) Yes b 
Pantoprazole 3,92 a 0,50 a   No b 
Piperazine Citrate 9,73 a -0,80 a   No b 
Pyrimethamine 7,34 a 2,7 a 2,41 (Sanderson, 2009) Yes b 
Quinine Sulfate B.P na 2,6 a 3,43 (Sanderson, 2009) Yes b 
Zidovudine 9,85c 0,05 a 0,23 (Sanderson, 2009) Yes b 
Reference: a - DrugBank. Wishart, 2010, b - Sweetman, 2007, c - Jjemba, 2006   
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Table 10 Biodegradability and removal of pharmaceuticals: background information  
Bioavailability, half life in organism, removal% in WWTP and Biodegradability 
Chemical 
Bioavailability 
% 
Half life 
Removal 
% 
Reference 
Biodegradability 
% 
Reference 
Amodiaquine HCl Readily av.  b 1-10d+  b 
  
  
Aspirin  
(Acetylsalicylic acid) 
na 0,25-9h  a 81 (Fent, 2005)   
Carbamazepine na 25-65h  a  
0-10 
7-8 
(Zhang, 2008) 
(Joss, 2005) 
(Ternes, 
1998) 
0 
(Ternes, 
2007) 
Dextrose Monohydrate na na 
  
  
Ethambutol HCl 80  a 3-4h  a     
Hydrocortisone Acetate Readily av.  b 6-8h  a 
  
  
Isoniazid Readily av.  b 1-6h  b       
Ketoconazole  Moderate  a, b 2-8h  b       
Lamivudine 87  a 5-7h  a       
Levamisole HCL na 4,4-5,6h  a 
  
  
Mebendazole 5-10  a 2,5-5,5h  a 
  
  
Metronidazole Benzoate 20-100  b 8h  a 
  
5 
(Kümmerer, 
2000) 
Nevirapine (viramune) 90  a 45h  a 
  
  
Ofloxacin USP 98  a 9h  a 
57 
56 
75 - 88 
(Gros, 2009) 
(Zorita, 2009) 
(Vieno, 2007) 
0 
(Kümmerer, 
2000) 
Pantoprazole 77  a,b 1h  a 
  
  
Piperazine Citrate 100  a na 
  
  
Pyrimethamine  100  b  96h  a       
Quinine Sulfate B.P 76-88  a 18h  a 
  
  
Zidovudine 65  a 0,5-3h  a 
  
  
Reference: a - DrugBank. Wishart, 2010, b - Sweetman, 2007
5 Experimental: Biodegradability analysis by OxiTop ® - C 110 
Base information on the biodegradability or removal from wastewater is incomplete for the 
chosen therapeutics. Therefore ready biodegradability was tested to obtain a starting value 
on the biological degradation potential.  
Based on the physico-chemical properties of the selected chemical species, manometric 
respirometry in a closed bottle system (CBS/CBT) was chosen as an appropriate test 
method. The main parameters for this decision were the solubility of tested substances and 
the test concentration. The water solubility ranged from freely soluble to practically 
insoluble substances. For manometric respirometry the test concentration is higher 
compared to other test methods, which was important parameter in order to maintain high 
accuracy of the solution preparation.    
In order to test large amount of pharmaceuticals and get needed accurate data, the 
automated OxiTop-C 110 system was chosen for the biodegradability analysis, see Figure 
4. 
 
Figure 4 OxiTop measuring system - (left) rubber sleeve as a CO2 trap, ATU and NaOH pellets, 
(middle) measuring vessel, rubber sleeve and measuring head, (right) Incubator and magnetic stirrer 
5.1 Principle  
The principle of the test was the measurement of CO2 produced by inoculated bacteria in a 
closed bottle system when pharmaceutical was added. Increasing concentration of CO2 
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trapped and measured by the head of OxiTop-C 110 system showed the progressing 
degradation process.  
The CO2 evolution is an indirect measurement method that can be easily presented as 
oxygen consumption, i.e. biological oxygen demand (BOD). As each pharmaceutical was 
tested individually as a sole source of carbon the biodegradation was presented as a ratio of 
theoretical oxygen demand (ThOD) and BOD (WTW, 2009, manual, 2000). 
5.2 Objective of the analysis 
The main target of the experimental part is the biodegradability analysis of the 
pharmaceuticals used extensively in developing countries. Based on biodegradation results, 
pharmaceuticals likely to enter and persist in the natural environments are identified.  
5.3 Theoretical Oxygen demand 
Theoretical oxygen demand (ThOD), used as a reference value in the final biodegradation 
evaluation, was calculated individually for selected substances using following equation (1) 
and formula (2) (Techobanoglous, 1987). 
CcHhOoNnPpSs + (c + 0,25h – 0,5o + 1,25n + 1,25p + 1,5s) O2 → cCO2 + (0,5h – 0,5n – 
1,5p – s) H2O + nNO3
-
 + pPO4
-3
 + sSO4
-2
 + (n + 3p + 2s) H
+
  (1) 
where small letters represent the amount of moles (c) carbon, (h) hydrogen, (o) oxygen, (n) 
nitrogen, (p) phosphorus and (s) sulfur.  
Equation (1) was used to calculate moles of oxygen n(O2) needed for complete oxidation of 
the organic compound. Value of n(O2) was then substituted to formula (2) to calculate the 
ThOD. 
              (2) 
where n(O2) is amount of moles of oxygen (mol), Mr(O2) is relative molecular weight of 
oxygen (g/mol), c(pharmaceutical) is the actual concentration used in the measurement 
(g/l), and Mr(pharmaceutical) is the relative molecular weight of pharmaceutical (g/mol).  
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To perform the BOD test the total oxygen in the CBS cannot become a limiting factor 
during the whole time of the experiment. Stating correct filling volume (the wastewater 
level in the bottle and amount of air above the water level) is a crucial moment in the 
experiment setting. ThOD was therefore used as an ideal reachable BOD value to set the 
correct filling volume and appropriate range of the measurement (WTW, 2009).  
5.4 Methods 
In this paragraph the methods and the setting of the analysis are described. Paragraph 5.4.1 
shows the composition and preparation of the mineral medium (the base solution of 
artificial wastewater), 5.4.2 describes the pharmaceutical solution preparation, inoculum 
and test conditions are described in 5.4.3 and 5.4.4 respectively. Endogenous BOD 
measurement is mentioned in 5.4.5. And finally the system test compounds are to be found 
from 5.4.6. 
5.4.1 Mineral medium 
In the biodegradability analysis, the tested compound has to be the sole source of carbon. 
To fulfill this condition a mineral medium of known composition resembling wastewater 
was prepared. The mineral medium composition can be found in OECD guidelines for 
testing chemicals on biodegradability (OECD(a), 1992), see Table 11. Chemicals used in 
the preparation were of pro-analysis purity purchased from Merck.  
Table 11 Mineral medium preparation according to OECD 301 
    Stock solution Mineral solution 
sol.  Chemical mass (g) V (ml) V (ml) Total V(ml) 
a KH2PO4  8,50 
1000 10 
1000 
  K2HPO4 21,75 
  Na2HPO4.2H2O 33,40 
  NH4Cl 0,50 
  
b CaCl2.2H2O 36,40 1000 1 
  
c MgSO4.7H2O 22,50 1000 1 
  
d FeCl3.6H2O 0,25 1000 1 
Reference: (OECD(a), 1992) 
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The final mineral solution was prepared by diluting 10ml of stock solution a in 800ml of 
distilled water, 1ml of each stock solution b, c, and d were added and filled to final volume 
of 1000ml. 
5.4.2 Test compound  
Each pharmaceutical was tested individually on the biodegradation. Test substances were 
received from UCL, Nairobi, Kenya as powders.  
Test concentration was 50mg/l. Rather high concentration was decided to maintain desired 
accuracy and because wastewater from pharmaceutical industry was in question. At this 
concentration in several cases toxic and inhibitory effects were expected based on available 
EC50 values. However the preference was given to the possibility of final comparison of the 
effects at the same concentration.  
Solutions of the test substances were prepared according to the water solubility based on 
given OECD 301 guidelines. Compounds with solubility over 1g/l were prepared into 
solutions with distilled water (1g/l) and adequate volume was transferred from the 
pharmaceutical stock solution to the test bottle. Solutions of sparingly (0,1g/l – 1g/l) 
soluble compounds were prepared from stock solution a. Adequate weight of poorly 
soluble and insoluble compounds was added to the ready mineral medium from a weighing 
vessel. The reason for described action was the water volume reduction in the system. 
Excess water could reduce the buffering capacity of prepared mineral medium and disturb 
the measurement; bacterial inoculum is often sensitive to pH change.      
5.4.3 Inoculum 
Activated sludge from Viinikanlahti wastewater treatment plant, Tampere, Finland was 
used as the bacterial inoculum. Fresh samples were taken each day of the measurement in 
the time period from May to September 2010. Inoculum was aerated and filtrated before the 
measurement. Each closed bottle system was added 0,5ml of inoculum.   
5.4.4 Test conditions 
Two different period lengths of biodegradation measurements were performed, 7 and 28 
days. The solutions were kept in dark and incubated at constant temperature 20±1°C. 20 
drops/l of N-Allylthiourea (C4H8N2S) ATU were used as a nitrification inhibitor. Three 
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replicates of each substance were measured. Each measurement round was accompanied 
with three blanks to measure endogenous BOD for final biodegradability correction. 
5.4.5 Endogenous BOD 
Endogenous BOD is the oxygen consumption from the basic respiration activity of starved 
bacteria without any added degradable substance. That means, blank system to measure 
endogenous BOD contained mineral medium, 0,5ml of inoculum and 20 drops ATU/l. The 
blank values were used for correction of the test values (Reuschenbach, 2003). 
According to the literature, the blank BOD value should range between 20mg/l - 60mg/l. If 
the value drops bellow 20mg/l, change of the procedure or system check-up is needed. 
(OECD(a), 1992, Reuschenbach, 2003) 
5.4.6 System test compounds 
System test compounds, dextrose monohydrate and carbamazepine were chosen to test the 
set conditions and the functionality of the test. Dextrose monohydrate was chosen as a 
ready biodegradable compound in order to gain a target degradation curve. Carbamazepine 
is a non-degradable compound with low percentage of WWTP removal. 
5.5 Results 
System test compounds, dextrose monohydrate was readily biodegradable, while 
carbamazepine was non-biodegradable. 
Out of following 17 compounds, only two PPCPs were readily biodegradable (aspirin and 
hydrocortisone acetate) and two compounds were low-degradable (metronidazole benzoate 
and piperazine citrate).  
13 compounds (excluding already mentioned carbamazepine) were non-biodegradable, 
toxic or inhibitory to activated sludge bacteria and potentially refractory in the 
environment. Therapeutics belonging to the non-degradable group were antiretrovirals, 
antimalarials, anthelminthics (excluding piperazine citrate), antibacterials (excluding 
metronidazole benzoate), antifungals, antituberculotics and antiulceratives. More detailed 
information on the observations can be found from the following paragraphs. 
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5.5.1 Endogenous BOD 
Endogenous BOD was measured every round with test compounds. The final endogenous 
BOD values ranged between 2,5 – 14,1mg/l, 7,0mg/l being the most common endogenous 
BOD value.  
Degradation curves for endogenous BOD7 and endogenous BOD28 can be seen from Figure 
5. No significant difference between the final values of the two measurement periods was 
observed.  
 
Figure 5 Endogenous BOD7 and endogenous BOD28 degradation curves. 
The functionality of the test was measured on degradability of system test compound, i.e. 
dextrose monohydrate, because the endogenous BOD was not in the recommended range 
20 – 60mg/l. Degradation curve of dextrose can be seen from Figure 6.  
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Figure 6 Degradation curve of dextrose monohydrate. Dextrose was tested as a system control 
compound on the degradation potential. Values in the chart are not corrected with endogenous BOD. 
Biodegradation of dextrose reached 73% in 7 days. The system setup was considered 
functional and no change was introduced. The low endogenous BOD was probably caused 
by the filtration of the suspended solids from the inoculum causing the decrease in the 
organic matter concentration. The initial lag phase, which can be seen from Figure 6, was 
caused most probably by temperature shock. 
5.5.2 BOD7 
Antiretrovirals (nevirapine and zidovudine), antibacterials (ethambutol, ofloxacin and 
metronidazole benzoate), antimalarials (amodiaquine and quinine sulfate) and 
anthelminthics (levamisole and mebendazole) were tested for BOD7. 
Except of metronidazole benzoate (18%), all tested chemicals degraded by less than 5% 
during 7 days, see Table 12. BOD7 value of amodiaquine was lower than the endogenous 
value of the corresponding measurement, which resulted in negative biodegradability 
percentage. 
All biodegradation curves of pharmaceuticals tested on BOD7 can be found from Appendix 
A Biodegradation curves: BOD7 
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Table 12 BOD7 of selected pharmaceuticals. ThOD - theoretical oxygen demand, BOD av. is average 
Biological oxygen demand calculated from 3 replicates, BOD corr. is the corrected BOD value with 
endogenous BOD of corresponding measurement. 
Chemical ThOD (mg/l) BOD av. (mg/l) BOD corr.(mg/l) Biodegradability% 
Amodiaquine Base 98,967 7,1 -0,7 -0,7% 
Ethambutol HCl 100,999 7,0 4,23 4% 
Levamisole HCL 121,288 7,0 0 0% 
Mebendazole 116,495 6,1 1,9 2% 
Metronidazole Benzoate 104,613 25,8 18,8 18% 
Nevirapine (viramune) 138,191 7,5 4,7 3% 
Ofloxacin USP 109,584 7,5 0,5 0,5% 
Quinine Sulfate B.P 112,463 5,1 0,9 0,8% 
Zidovudine 104,774 7,5 4,7 4% 
 
5.5.3 BOD28 
Anti-inflammatory aspirin, glucocorticoid hydrocortisone acetate, antiulcerative 
pantoprazole, antiretroviral lamivudine, antiepileptic carbamazepine (system test 
compound), antibacterial isoniazid, anthelmintic piperazine citrate, antifungal ketoconazole 
and antimalarial pyrimethamine were tested for BOD28. 
Table 13 BOD28 of selected pharmaceuticals. ThOD - theoretical oxygen demand, BOD av. is average 
Biological oxygen demand calculated from 3 replicates, BOD corr. is the corrected BOD value with 
endogenous BOD of corresponding measurement. 
Chemical ThOD (mg/l) BOD av. (mg/l) BOD corr. (mg/l) Biodegradability% 
Aspirin (Acetylsalicylic acid) 
79,930 52,6 46,07 58% 
Carbamazepine 
135,439 8,9 -2,8 -2% 
Hydrocortisone Acetate 
110,754 78,5 71,9 65% 
Isoniazid 
128,337 9,9 -1,87 -1% 
Ketoconazole 
129,462 4,2 1,9 1% 
Lamivudine 
101,197 8,5 -3,3 -3% 
Pantoprazole 
95,991 12,7 6,17 6% 
Piperazine Citrate  
89,622 36,1 31,9 36% 
Pyrimethamine 
130,272 4,2 1,9 1% 
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Anti-inflammatory Aspirin (58%) and glucocorticoid hydrocortisone acetate (65%) were 
considered readily biodegradable compounds based on the observed BOD value and on the 
shape of the degradation curve. Anthelmintic piperazine citrate was considered degradable 
(36%).  
Based on the shape of the biodegradation curve with a mild and slow increase of the BOD 
value (Appendix B), antiulcerative pantoprazole was identified as a compound with 
inhibitory effects to activated sludge. 
Carbamazepine, isoniazid, ketoconazole, lamivudine and pyrimethamine pose toxic effects 
towards activated sludge bacteria.   
Charts of all PPCPs mentioned in this paragraph can be found from Appendix B 
Biodegradation curves: BOD28. 
5.5.4 Observation of OxiTop-C 110 
OxiTop-C 110 system is a very easy and fast screening method for ready biodegradability 
analysis. The system does not require controlling and tested compounds are individually 
sampled in regular intervals which would under different circumstances require time. The 
length of intervals depends on the whole measuring time, the sampling covers the chosen 
testing period completely with 360 samples. 
What was observed was rather high fluctuation of the BOD value in several cases, for 
example mebendazole benzoate. Even more, especially for non-biodegradable compounds 
where the BOD value was low, certain similarity in the reached values was observed. It 
seams that the system is able to record the values in steps, discrete values. As an example a 
short row of values reached during the whole screening are shown: 0; 1,4; 2,8; 4,2; 5,6; 7,0. 
Values in between were not reached, which in the cases of low BOD might cause accuracy 
problem. This phenomenon can explain the fluctuating values visible from presented charts.   
   
6 Conclusion 
During last two decades, research studies on the occurrence and fate of PPCPs in the 
environment commonly used in developed world have been published. PPCPs have been 
recently detected from soils, sediments, surface or groundwater around the world. 
Furthermore, the behavior of PPCPs in the WWTP and the removal from the wastewater 
has become an important question. 
This study provided information on the biodegradability of PPCPs frequently used in 
developing world that are lacking knowledge on their WWTP removal, behavior in the 
environment and occurrence and fate in the aquatic and terrestrial ecosystems.  
Ready biodegradability test according to OECD 301 guidelines was performed on selected 
PPCPs. Screening with OxiTop-C 110 based on the manometric respirometry was 
performed. Chosen method allowed collection of large amount of data on the 
biodegradability process and enabled clear presentation of the results. A question appeared 
following the values reached during individual measurements. The system seems to reach 
only discrete values of BOD. This becomes only visible when low-degradable and non-
degradable compounds are tested and raises a question of accuracy in these measurements.  
Therapeutic groups preferred in the experiment were antiretrovirals, antibacterials, 
antimalarials, anthelmintics, antituberculotics, antifungals, antiulceratives and 
glucocorticoids.  
Because of limited knowledge available on the selected chemical species, biodegradable 
dextrose monohydrate and non-biodegradable antiepileptic carbamazepine were chosen as 
system test compounds (Heberer, 2002). Both drugs behaved as was expected based on the 
background information. Performed test results were therefore considered valid for all 
tested compounds. 
From the tested pharmaceuticals only anti-inflammatory aspirin and glucocorticoid 
hydrocortisone acetate were found readily biodegradable. The results for aspirin comply 
with the literature data (Fent, 2005). 
Conclusion  54/73 
All tested antiretrovirals (anti-HIV drugs), zidovudine, lamivudine and nevirapine were 
found non-biodegradable during the simulated WWTP biological treatment in a CBS. There 
are no reference data available on the therapeutic group, however the results were 
considered valid due to consistency with results of the test compounds. All anti-HIV drugs 
are potential environmental pollutants. Nevirapine should be high lightened in this group 
because of its long half life, high toxicity to higher organisms (rat) and stability when 
exposed to light. 
From the group of antibacterials, ethambutol HCl and ofloxacin did not degrade during the 
same test. The biodegradability of ofloxacin was 0,5% which is consistent with the 
literature data (0%) mentioned in paragraph 4.4 (Kümmerer, 2000). Higher percentage of 
removal during WWTP shows on possible other processes taking place next to 
biodegradation (Vieno, 2007, Fent, 2005). The biodegradation value of metronidazole 
benzoate was measured 18%, which is higher than the background information (5%) 
(Kümmerer, 2000).  
All tested antimalarials, amodiaquine, quinine sulfate and pyrimethamine were found non-
biodegradable. Similarly to antiretrovirals, for the therapeutic group of antimalarials there 
are no available literature data on their biodegradability. The observed biodegradation 
values ranged from -0,7% to 1%. Therefore antimalarials were considered toxic to activated 
sludge bacteria.  
In the group of anthelminthics, piperazine citrate degraded by 36%. Mebendazole and 
levamisole were toxic to activated sludge bacteria based on the BOD value and on the 
biodegradation curve. This statement is supported by the EC50 value tested on activated 
sludge bacteria for levamisole, see paragraph 4.2. The low EC50 value is indicating the 
toxicity to sludge bacteria (Basnyat, 2010). 
Antitubercular isoniazid was found non-biodegradable. The negative biodegradability 
percentage (Table 13), low AO LD50 dose and low EC50 (Sanderson, 2009) values for 
Daphnids and for algae are suggesting that isoniazid might be toxic to sludge bacteria. 
Conclusion  55/73 
Antifungal ketoconazole and antiulcerative pantoprazole were found non-biodegradable. 
Based on the observed values and biodegradation curves ketoconazole was considered toxic 
to sludge bacteria and pantoprazole inhibitory. 
Based on the observations, all non-biodegradable and low- biodegradable compounds 
studied in this thesis should be excluded from the wastewater. These chemicals can 
potentially pass WWTP processes and enter the natural environment causing water and soil 
pollution. Secondly, the constant exposure to these xenobiotics can cause the development 
of resistant species of viruses, bacteria or protozoa. Resistant species would consequently 
increase the demand for stronger therapeutics increasing also the negative effect on the 
environment. And finally, toxic and inhibitory compounds could decrease the efficiency of 
WWTP biological processes by decreasing the bacterial population and cause secondary 
pollution.  
  
   
7 Discussion and future work 
The results of this thesis raise several important questions. First of all, I would like to 
emphasize that the used inoculum was sampled at a WWTP in Finland and therefore the 
bacteria have possibly never before been exposed to most of the tested chemicals. This 
could explain the large number of refractory compounds. On the other hand though, such 
first exposure shows truly the potential to affect the natural populations. It would be 
interesting to subject the same therapeutics to the same test with inoculum exposed earlier 
to these xenobiotics. Such experiment could present accommodation ability of the sludge 
bacteria or the potential for resistant population development.  
Another problem that can be identified is the question of the toxic and inhibitory chemicals 
in the WWTP influent. It is clear that the toxic impact reduction during the biological 
treatment requires innovative wastewater treatment processes or source separation to reduce 
the chemical concentration entering sewage system. Intervention at the source could be 
feasible when industrial production is in questions. The reduction of water used for 
equipment cleaning, cleaning with compressed air, isolating cleaning water from the rest of 
grey and black water and introduce separate treatment techniques are only few theoretical 
ideas of possible actions to undertake.       
Isolating the industrial wastewater from the household wastewater would be beneficial also 
for the recovery of the pharmaceuticals and reduction of the wastewater volume. Ozonation 
is one of the innovative methods of refractory compound treatments. This method involves 
ozone generation which is energy demanding and expensive. Reduction of the wastewater 
volume could reduce the costs and make the method more accessible. Furthermore, it is 
more than obvious that development of new innovative treatment methods is necessary. 
Fourth point is not tightly connected to the content of this thesis. Nevertheless, I would like 
to mention the problem of PPCPs and their residues that are excreted from receiving 
organisms via urine or feces. In developed countries with sufficient sanitation systems, 
these enter the centralized sewage system from household wastewater and travel to 
municipal WWTP. In the WWTP, these can affect the efficiency of the treatment. In 
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developing countries the situation is even more complicated due to insufficient sanitation. It 
is of course not clear, but this route could be the main pathway causing the reported 
occurrence of PPCPs in the environment. Again, the behavior in black and yellow water, 
soils, surface and ground water and the potential effect on the organisms should be widely 
studied and treatment processes developed. 
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Figure 7 Biodegradation curve: Zidovudine 
 
Figure 8 Biodegradation curve: Nevirapine 
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Figure 9 Biodegradation curve: Ethambutol HCl 
 
Figure 10 Biodegradation curve: Ofloxacin 
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Figure 11 Biodegradation curve: Metronidazole benzoate 
 
Figure 12 Biodegradation curve: Quinine sulfate 
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Figure 13 Biodegradation curve: Amodiaquine 
 
Figure 14 Biodegradation curve: Mebendazole 
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Figure 15 Biodegradation curve: Levamisole 
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Appendix B Biodegradation curves: BOD28 
 
Figure 16 Biodegradation curve: Aspirin 
 
Figure 17 Biodegradation curve: Hydrocortisone acetate 
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Figure 18 Biodegradation curve: Pantoprazole 
 
Figure 19 Biodegradation curve: Carbamazepine 
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Figure 20 Biodegradation curve: Lamivudine 
 
Figure 21 Biodegradation curve: Isoniazid 
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Figure 22 Biodegradation curve: Ketoconazole 
 
 Figure 23 Biodegradation curve: Pyrimethamine  
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Figure 24 Biodegradation curve: Piperazine Citrate 
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